 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- HSK29116 / Haisco
Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies (Section 46; Poster Board #16) - Mar 14, 2023 - Abstract #AACR2023AACR_4826;
P1
Exploratory analyses will evaluate the relationship between HSK29116 anti-tumor activity and BTK gene mutations, as well as BTK protein degradation effects of HSK29116 . Descriptive statistics will be used to summarize all data.
- ||| HSK29116 / Haisco
Enrollment open: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Aug 3, 2022
P1, N=156, Recruiting, Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Descriptive statistics will be used to summarize all data. Not yet recruiting --> Recruiting
- ||| HSK29116 / Haisco
New P1 trial: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Apr 26, 2021
P1, N=126, Not yet recruiting, Sponsor: Haisco Pharmaceutical Group Co., Ltd.